您是第 11226983 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

B-CPAP人甲状腺癌细胞(STR鉴定)

英文名:B-CPAP
货号:ZQ0304
价格:¥1800.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

B-CPAP人甲状腺癌细胞(STR鉴定)

¥1800.00
+

B-CPAP人甲状腺癌细胞专用培养基

¥700.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥2500
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

B-CPAP人甲状腺癌细胞

货号

ZQ0304

产品介绍

B-CPAP 是一种人类乳头状甲状腺癌细胞系,于1992年从一名罹患转移性甲状腺乳头状癌的76岁女性的肿瘤组织中建立。该细胞系表现出上皮样形态,常用于研究甲状腺癌生物学,包括肿瘤发生和转移机制。B-CPAP 细胞因携带 BRAF V600E 突变而著名,这是一种与侵袭性甲状腺癌相关的常见基因变异,是评估 BRAF 抑制剂作为治疗剂的关键模型。

除了 BRAF 突变外,B-CPAP 细胞还表达甲状腺特异性标志物,如甲状腺球蛋白和促甲状腺激素受体,使其成为研究甲状腺功能和病理的宝贵模型。它们已广泛用于研究与甲状腺癌进展有关的信号通路,包括 MAPK/ERK 通路激活。这些细胞还用于药物耐药性和细胞凋亡研究,为甲状腺癌治疗失败的机制提供了见解。

种属

性别/年龄

女/76岁

组织

甲状腺

疾病

甲状腺癌

细胞类型

肿瘤细胞 

形态学

纺锤状或圆形细胞贴壁生长成单层细胞

生长方式

贴壁

倍增时间

大约30小时 

培养基和添加剂

RPMI-1640(中乔新舟 货号:ZQ-200)+10%胎牛血清(中乔新舟 货号:ZQ0500)+1%P/S(中乔新舟  货号:CSP006)+1%Non-essential Amino Acids, 100X (中乔新舟  货号:CSP008)+ +1% Sodium Pyruvate 100 mM Solution(中乔新舟  货号:CSP003)+1%L-alanyl-L-glutamine(中乔新舟   货号:CSP004

推荐完全培养基货号

ZM0304

生物安全等级

BSL-1

STR位点信息

Amelogenin: X;

CSF1PO: 13
D2S1338:18
D3S1358:16,17
D5S818: 10,11
D7S820: 10
D8S1179:12,13
D13S317:12
D16S539:11,12
D18S51: 13,17
D19S433:13.2,15 (PubMed=25877200)
             :14,15 (DSMZ=ACC-273)
D21S11: 30 (DSMZ=ACC-273)
           :30,31.2 (PubMed=18713817; PubMed=25877200; PubMed=30737244)
FGA:20,23
Penta D: 10,11
Penta E: 5,12 (DSMZ=ACC-273)
            :5,12,17 (PubMed=25877200)
TH01:6,9.3
TPOX:8,11
vWA:14,17

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

DSMZ; ACC-273

供应限制

仅供科研使用


货号

ZQ0304

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


论文标题: Hypomethylated gene RAC3 induces cell proliferation and invasion by increasing FASN expression in endometrial cancer
DOI:10.1016/j.biocel.2022.106274. Epub 2022 Jul 30
发表时间: 2022-8-1
期刊: The International Journal of Biochemistry & Cell Biology
影响因子: 3.4
货号: ZQ0304
产品名称:  BCPAP cells
原文链接:https://www.sciencedirect.com/science/article/abs/pii/S1357272522001194?via%3Dihub


论文标题: Identification and Application of an Aptamer Targeting Papillary Thyroid Carcinoma Using Tissue-SELEX

DOI: 10.1021/acs.analchem.9b01000
发表时间: 2019-05-29
期刊: ANALYTICAL CHEMISTRY
影响因子: 6.35
货号: ZQ0304
产品名称: BCPAP cells

原文链接: https://pubs.acs.org/doi/abs/10.1021/acs.analchem.9b01000



PubMed=1297527
Paulin C., Fabien N., Fusco A., Pages M.-P., Patricot M.-C., Bornet H., Dubois P.-M.
Description of a cell line established from a human thyroid papillary carcinoma and synthesizing human chorionic gonadotropin hormone.
C. R. Acad. Sci. III, Sci. Vie 315:493-498(1992)


PubMed=8156527; DOI=10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M
Fabien N., Fusco A., Santoro M., Barbier Y., Dubois P.-M., Paulin C.
Description of a human papillary thyroid carcinoma cell line Morphologic study and expression of tumoral markers.
Cancer 73:2206-2212(1994)


PubMed=11439348; DOI=10.1038/sj.onc.1204531
Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor.
Oncogene 20:3845-3856(2001)


PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)


PubMed=15172756; DOI=10.1016/j.cancergencyto.2003.09.023
Dettori T., Frau D.V., Garcia J.L., Pierantoni G.M., Lee C., Hernandez J.M., Fusco A., Morton C.C., Vanni R.
Comprehensive conventional and molecular cytogenetic characterization of B-CPAP, a human papillary thyroid carcinoma-derived cell line.
Cancer Genet. Cytogenet. 151:171-177(2004)


PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)


PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026
van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.
Cancer Res. 67:8113-8120(2007)


PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)


PubMed=19087340; DOI=10.1186/1471-2407-8-371
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371.1-371.11(2008)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)


PubMed=22087789; DOI=10.1186/1755-8166-4-26
Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.
Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations.
Mol. Cytogenet. 4:26.1-26.8(2011)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=23162534; DOI=10.3389/fendo.2012.00133
Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.
Thyroid cancer cell lines: an overview.
Front. Endocrinol. 3:133.1-133.9(2012)


PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)


PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)


PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


PubMed=28775782; DOI=10.7150/jca.18855
Caria P., Pillai R., Dettori T., Frau D.V., Zavattari P., Riva G., Romano G., Pani F., Bentivegna A., Giovannoni R., Pagni F., Sogos V., Vanni R.
Thyrospheres from B-CPAP cell line with BRAF and TERT promoter mutations have different functional and molecular features than parental cells.
J. Cancer 8:1629-1639(2017)


PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)


PubMed=32666385; DOI=10.1007/s12020-020-02417-y
Run L., Wang L.-P., Nong X.-T., Li N., Huang X., Xiao Y.
Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
Endocrine 71:418-426(2021)


PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)


相关产品
货号 产品名称 规格 价格 指令
ZQ0281 TTA1人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1500.00 放入购物车 》
ZQ0305 8305C人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1350.00 放入购物车 》
ZQ0310 ACT-1人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1500.00 放入购物车 》
ZQ0311 CAL-62人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1350.00 放入购物车 》
ZQ0312 BHT101人甲状腺癌细胞(STR鉴定) 1 x 10^6 cells/vial ¥1800.00 放入购物车 》
ZQ0314 HTh-7人甲状腺癌细胞(STR鉴定)[套餐促销] 5 x 10^5 cells/vial ¥1200.00 放入购物车 》
ZQ0315 Hth83人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1600.00 放入购物车 》
ZQ0316 KHM-5M人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1350.00 放入购物车 》
ZQ0317 KMH-2人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1500.00 放入购物车 》
ZQ0318 KTC-1人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1350.00 放入购物车 》
ZQ0319 Ocut-2C人甲状腺癌细胞(STR鉴定) 5 x 10^5 cells/vial ¥1600.00 放入购物车 》
ZQ0321 C643人甲状腺癌细胞(STR鉴定)[套餐促销] 5 x 10^5 cells/vial ¥1350.00 放入购物车 》
A1001-1 国产转染试剂 1ml ¥800.00 放入购物车 》
1 慢病毒介导基因沉默或过表达 ¥询价 放入购物车 》
ZQ500 国产优级胎牛血清 500ml ¥1800.00 放入购物车 》
3 细菌基因敲除 ¥询价 放入购物车 》
ZQ-200 RPMI-1640基础培养基 500ml ¥56.00 放入购物车 》
ZQ-201 RPMI-1640完全培养基 500ml ¥350.00 放入购物车 》
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
      上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经十多年发展,...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号